Ludwig Enterprises Announces Acceptance of Two Abstracts in the Journal of Clinical Oncology MIAMI, FLORIDA / ACCESS Newswire / April 29, 2025 / Ludwig Enterprises, Inc. (the “Company”), a leading biotech and healthcare firm, announced today that two abstracts related to its mRNA cancer screening program have been accepted for publication in the Journal of Clinical Oncology. The abstracts, titled “Non-invasively Collected Buccal Cell mRNA Reveals Novel Breast Cancer Signal” and “A Novel Machine Learning Approach to Breast Cancer Screening Using Non-invasive mRNA Collection,” highlight the company’s innovative methods in early cancer detection. Dr. Marvin S. Hausman, the Company’s Chief Scientific Officer (CSO), expressed excitement about the upcoming American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, scheduled from May 30 to June 3. He stated, “The ASCO 2025 Annual Meeting offers a unique platform to present and discuss our proprietary mRNA cancer screening program with major laboratories, telehealth providers, and pharmaceutical companies. This gathering of leading experts and stakeholders is an ideal setting to showcase what we believe to be our groundbreaking cancer diagnostic technology.” The scientific and marketing teams from Ludwig Enterprises plan to attend the conference to engage with clinical trial investigators, laboratory experts, and pharmaceutical industry leaders. They will share details about their cancer diagnostic program and the impending launch of their new non-invasive cheek cell breast cancer test, which leverages advanced mRNA analysis and machine learning algorithms. About Ludwig Enterprises, Inc. Ludwig Enterprises, Inc., soon to be known as Revealia Diagnostics, Inc., is a global innovator in mRNA genomics and machine learning AI technology. The company’s primary mission is to identify, monitor, and develop solutions to mitigate chronic inflammation, a key factor in illnesses such as cancer and heart disease, which account for over 50% of global deaths. About Revealia Diagnostics™ Revealia™ is a revolutionary breast cancer screening test that uses a proprietary mRNA microarray to generate a personalized inflammatory index. This index provides patients with reliable information to guide their healthcare decisions. By employing artificial intelligence (AI), the test calculates a risk score based on a specific array of inflammatory biomarkers, which is then compared to a database of previously analyzed patients. Forward-Looking Statements This press release contains forward-looking statements made under the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. These statements pertain to future business levels for the Company and are subject to various risks and uncertainties. While Ludwig Enterprises Inc. aims to achieve the projected outcomes, there is no guarantee that the actual results will match these expectations. Potential risks and uncertainties include the company’s ability to secure, price, and complete projects, as well as changes in product offerings and competitive dynamics. For Further Information: Contact: Ludwig Enterprises, Inc. www.ludwigent.com Twitter: @LUDG_inc Charles Todd, Jr. [email protected] Source: Ludwig Enterprises, Inc. View the original press release on ACCESS Newswire.